Cyclooxygenase-2 inhibitors in colorectal cancer

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 10-16

  Stoehlmacher, Jan ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIOGENESIS; APOPTOSIS; CANCER INCIDENCE; COLORECTAL CANCER; ENTERITIS; ENZYME INHIBITION; FAMILIAL COLON POLYPOSIS; GENE OVEREXPRESSION; HUMAN; IMMUNITY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 0038515000     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70020-7     Document Type: Article

References (56)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
2. Cascante M, Boros LG, Comin-Anduix B, et al: Metabolic control analysis in drug discovery and disease. Nat Biotechnol 20:243-249, 2002
3. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J 12:1063-1073, 1998
4. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140, 1996
5. Herschman HR, Xie W, Reddy S: Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Bioessays 17:1031-1037, 1995
6. Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994
7. Vane JR, Flower RJ, Botting RM: History of aspirin and its mechanism of action. Stroke 21:IV12-IV23, 1990 (suppl 12)
8. Hirschowitz BI, Lanas A: Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 34:523-528, 2002
9. Laine L, Harper S, Simon T, et al: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776-783, 1999
10. Emery P, Zeidler H, Kvien TK, et al: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354:2106-2111, 1999
11. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24:83-87, 1983
12. Thun MJ, Henley SJ, Patrono C: Nonsteroidal antiinflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266, 2002
13. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991
14. Rosenberg L, Louik C, Shapiro S: Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82:2326-2333, 1998
15. Giovannucci E, Rimm EB, Stampfer MJ, et al: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-246, 1994
16. Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995
17. Gridley G, McLaughlin JK, Ekbom A, et al: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311, 1993
18. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
19. Labayle D, Fischer, D, Vielh P, et al: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639, 1991
20. Nugent KP, Farmer KC, Spigelman AD, et al: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618-1619, 1993
21. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
22. Boolbol SK, Dannenberg AJ, Chadburn A, et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996
23. Beazer-Barclay Y, Levy DB, Moser AR, et al: Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17:1757-1760, 1996
24. Jacoby RF, Marshall DJ, Newton MA, et al: Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56:710-714, 1996
25. Oshima M, Murai N, Kargman S, et al: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61: 1733-1740, 2001.
26. Reddy BS, Rao CV, Rivenson A, et al: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14:1493-1497, 1993
27. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apcdelta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996
28. Williams CS, Tsujii M, Reese J, et al: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589-1594, 2000
29. Neufang G, Furstenberger G, Heidt M, et al: Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A 98:7629-7634, 2001
30. Liu CH, Chang SH, Narko K, et al: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569, 2001
31. Chulada PC, Thompson MB, Mahler JF, et al: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705-4708, 2000
32. Kargman SL, O'Neill GP, Vickers PJ, et al: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559, 1995
33. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789, 1995
34. Kinzler KW, Vogelstein B: Landscaping the cancer terrain. Science 280:1036-1037, 1998
35. Chapple KS, Cartwright EJ, Hawcroft G, et al: Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156:545-553, 2000
36. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311, 2000
37. Shattuck-Brandt RL, Varilek GW, Radhika A, et al: Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 118: 337-345, 2000
38. Majima M, Hayashi I, Muramatsu M, et al: Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 130:641-649, 2000
39. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336-3340, 1997
40. Dormond O, Foletti A, Paroz C, et al: NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7:1041-1047, 2001
41. Sonoshita M, Takaku K, Sasaki N, et al: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7:1048-1051, 2001
42. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501, 1995
43. Chan TA, Morin PJ, Vogelstein B, et al: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 95:681-686, 1998
44. Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566-4569, 1996
45. Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237, 1992
46. Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5q21. Science 253:661-665, 1991
47. Khan KN, Masferrer JL, Woerner BM, et al: Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 36:865-869, 2001
48. Azumaya M, Kobayashi M, Ajioka Y, et al: Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis. Pathol Int 52:272-276, 2002
49. Phillips RK, Wallace MH, Lynch PM, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002
50. Blanke CD, Benson AB, Dragovich T, et al: A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 21:127a, 2002 (abstr 505)
51. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al: Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58:5473-5477, 1998
52. Sinicrope FA, Lemoine M, Xi L, et al: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117:350-358, 1999
53. Singer II, Kawka DW, Schloemann S, et al: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297-306, 1998
54. Newberry RD, Stenson WF, Lorenz RG: Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med 5:900-906, 1999
55. Reuter BK, Asfaha S, Buret A, et al: Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085, 1996
56. Agoff SN, Brentnall TA, Crispin DA, et al: The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157:737-745, 2000